Background. The outcome of percutaneous coronary intervention (PCI) is apparently worse in patients receiving a prior thrombolytic therapy ("facilitated PCI'). Recombinant tissue-type plasminogen activator (rt-PA) can degrade circulating high-density lipoproteins (HDL) bound apolipoprotein A-I (apoA-I), thus possibly reducing the vascular protective activity. There have never been reports of the detection of apolipoprotein breakdown products in the circulation. Aim. We studied the potential interactions between the protein components of HDL and tenecteplase, infused as thrombolytic therapy. Methods. Sera from a total of 40 patients with acute myocardial infarction (AMI), unstable angina (UA), and dilative cardiomyopathy (controls) were investigated. AMI patients underwent either immediate PCI or were treated with tenecteplase thrombolysis. Results. Products of extensive proteolysis of apoA-I were found in many acute coronary patients treated with tenecteplase, and in some AMI patients before starting the treatment (time 0). These were not detected in controls, UA patients as well as AMI patients undergoing immediate PCI. Small pre-beta-HDLs were selectively degraded. Conclusion. Significant apoA-I degradation occurs in AMI patients after thrombolytic treatment. This finding may provide a potential mechanism for the apparent reduction of benefit of facilitated versus nonfacilitated PCI.

Apolipoprotein A-I breakdown is induced by thrombolysis in coronary patients / I. Eberini, E. Gianazza, L. Breghi, S. Klugmann, L. Calabresi, M. Gomaraschi, G. Mombelli, B. Brusoni, R. Wait, C.R. Sirtori. - In: ANNALS OF MEDICINE. - ISSN 0785-3890. - 39:4(2007), pp. 306-311.

Apolipoprotein A-I breakdown is induced by thrombolysis in coronary patients

I. Eberini
Primo
;
E. Gianazza
Secondo
;
L. Calabresi;M. Gomaraschi;C.R. Sirtori
Ultimo
2007

Abstract

Background. The outcome of percutaneous coronary intervention (PCI) is apparently worse in patients receiving a prior thrombolytic therapy ("facilitated PCI'). Recombinant tissue-type plasminogen activator (rt-PA) can degrade circulating high-density lipoproteins (HDL) bound apolipoprotein A-I (apoA-I), thus possibly reducing the vascular protective activity. There have never been reports of the detection of apolipoprotein breakdown products in the circulation. Aim. We studied the potential interactions between the protein components of HDL and tenecteplase, infused as thrombolytic therapy. Methods. Sera from a total of 40 patients with acute myocardial infarction (AMI), unstable angina (UA), and dilative cardiomyopathy (controls) were investigated. AMI patients underwent either immediate PCI or were treated with tenecteplase thrombolysis. Results. Products of extensive proteolysis of apoA-I were found in many acute coronary patients treated with tenecteplase, and in some AMI patients before starting the treatment (time 0). These were not detected in controls, UA patients as well as AMI patients undergoing immediate PCI. Small pre-beta-HDLs were selectively degraded. Conclusion. Significant apoA-I degradation occurs in AMI patients after thrombolytic treatment. This finding may provide a potential mechanism for the apparent reduction of benefit of facilitated versus nonfacilitated PCI.
Angioplasty; Myocardial infarction; Plasminogen activator; Proteolysis; Tenecteplase
Settore BIO/14 - Farmacologia
Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
Settore BIO/10 - Biochimica
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/36511
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 17
social impact